On­coIm­mune pulls in $56M Se­ries B, hop­ing GvHD pro­gram can prove use­ful for Covid-19

A lit­tle over three and a half years since com­ing out of stealth, On­coIm­mune is back with a new fundraise.

The Mary­land-based biotech an­nounced a $56 mil­lion Se­ries B ear­ly Wednes­day morn­ing, seek­ing to sup­port two Phase III tri­als for its lead pro­gram CD24Fc. The can­di­date is be­ing test­ed in the treat­ment of se­vere Covid-19 cas­es in one study and leukemia pa­tients prone to acute GVHD in the oth­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER